News
Health Canada approves Trikafta for cystic fibrosis patients ages 12 and older who have at least one F508del mutation.-Vertex Pharma
Vertex Pharmaceuticals Incorporated announced Health Canada has granted Marketing Authorization for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the most common CF-causing mutation.
With this approval, for the first time, approximately 1,100 eligible patients with CF ages 12 years and older who have at least one F508del mutation have a medicine that targets the underlying cause of their CF.
Condition: Cystic Fibrosis-F508del-gene
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins